Malignant brain tumor cells (None)

Malignant brain tumor cells are neoplastic cells within the central nervous system that exhibit uncontrolled proliferation and the capacity to invade adjacent neural tissues (National Cancer Institute). These cells are characterized by significant genetic instability and the activation of oncogenic pathways, such as the PI3K/AKT/mTOR and MAPK/ERK pathways, which drive their aggressive phenotype (PubMed, PMID: 31636530). Although often referred to as a target in clinical oncology, they represent a heterogeneous disease state rather than a specific molecular entity like a receptor or enzyme. Therapeutic intervention typically involves a combination of surgical resection, radiation, and pharmacotherapy using agents like Temozolomide, which targets DNA replication, or Bevacizumab, which targets the tumor's blood supply (StatPearls). A major hurdle in treating these cells is the blood-brain barrier, which limits the delivery of many anti-cancer agents to the site of the tumor (NIH). Furthermore, the presence of glioma stem cells contributes to high rates of recurrence and resistance to standard-of-care treatments.

Other names

Brain cancer cellsGlioma cellsGlioblastoma cellsCNS malignancyNeoplastic brain cells

Therapeutic strategies involve DNA alkylation to induce cell death, inhibition of angiogenesis to restrict nutrient supply, and targeting specific signaling pathways like the PI3K/AKT/mTOR axis to inhibit growth.